Thursday, March 23, 2017 5:49:20 PM
We are the ones stuck with shares in the teens, 20s and 30s and may never see the light of getting back to that range when management continues to hand themselves tens of millions of shares at a time. They got 10 million bonus shares each for HemaX approval and here we stand, over a year later with nothing, no effort to bring it to human trials. NADA.
Now they trade their shares in for special new category shares that any buyout will pay first and maybe at a higher rate, leaving the crumbs to us. On top of it, they write in advance that any kind of leasing of the NR2F6 property (without qualifications) grants them 40M shares each or doubles the current outstanding shares. And since they'll need more money for development, they'll sell themselves even more shares at heavy discounts, all in the interest of shareholders of course.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM